Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.

  title={Long-term daclizumab therapy in relapsing-remitting multiple sclerosis.},
  author={M{\'o}nica Alvarado Rojas and Noel G. Carlson and Thomas L. Miller and John W. Rose},
  journal={Therapeutic advances in neurological disorders},
  volume={2 5},
We performed a retrospective review of side effects and clinical outcomes in relapsing-remitting (RR) multiple sclerosis (MS) patients receiving long-term treatment with daclizumab. Twelve patients with RR MS were initially treated with daclizumab at 1 mg/kg IV, again 14 days later and then monthly treatments (average duration 42.1 months). Daclizumab dose (0.85 mg/kg to 1.5 mg/kg) was adjusted based on clinical response. Daclizumab was generally well tolerated. There was a significant… CONTINUE READING